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INTRODUCTION
The National Surgical Infection Prevention Project (NSIPP)
has recommended prophylactic cefotetan administration to
prevent infections in colorectal surgery patients, and cefote-
tan is currently the most commonly prescribed prophylactic
antimicrobial agent in the United States (1). Although tra-
ditional triple antibiotic prophylaxis (aminoglycoside, an anti-
anaerobic, and penicillin) is now only used by a small propor-
tion of surgeons in the United States (2), it remains common
in other countries (3, 4).
Although many studies have evaluated antimicrobial pro-
phylaxis for preventing infections after colorectal surgery (5-
10), none has compared cefotetan alone with traditional triple
antibiotic treatment. Our center used a combination of cefa-
zolin, metronidazole and gentamicin as prophylactic antibi-
otics in colorectal cancer surgery until June 2007. In accor-
dance with the NSIPP recommendations, from July 2007,
our institute switched to use cefotetan alone for this purpose.
The present study compared infectious outcomes in elective
colorectal cancer surgery patients treated with cefotetan alone
or conventional triple antibiotics.
MATERIALS AND METHODS
From January to December 2007, 648 consecutive patients
underwent surgery for primary colorectal cancer at the Cen-
ter for Colorectal Cancer, National Cancer Center, Korea. The
inclusion criteria for the study were: 1) elective surgery, 2) cura-
tive intent surgery with standard lymph node dissection, 3)
no combined surgery involving other organs, and 4) no evi-
dence of infection at the time of surgery. Of the initial 648
patients, 187 were excluded from the study due to combined
surgery with other organs (74), palliative surgery (limited resec-
tion or diverting stoma creation only) (64), allergies to peni-
cillin or metronidazole (37), local procedures such as transanal
excision or transanal endoscopic microsurgery (10) and emer-
gency surgery (2) for homogenous inclusions. The remaining
461 patients were analyzed for the study. The study was per-
formed in accordance with the guidelines of our Institution-
al Review Board (NCCNCS-08-131). 
Patients were grouped based on their prophylactic antibi-
otic protocol. Group A=a conventional triple antibiotic combi-
nation of cefazolin (Cefamezin, Dong-A Pharm, Seoul, Korea),
metronidazole (Trizele, Choongwae Pharma, Seoul, Korea)
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This study examined infectious outcomes in elective colorectal cancer surgery bet-
ween cefotetan alone or conventional triple antibiotics. From January to December
2007, 461 consecutive primary colorectal cancer patients underwent elective surgery.
Group A contained 225 patients who received conventional triple antibiotics (cepha-
losporin, aminoglycoside and metronidazole) for prophylaxis, and group B contained
236 patients who received cefotetan alone for prophylaxis. Treatment failure was
defined as the presence of postoperative infection including surgical-site infection
(SSI), anastomotic leakage, and pneumonia or urinary tract infection. The two groups
were similar in terms of demographics, American Society of Anesthesiologists (ASA)
score, tumour location, stage, surgical approach (conventional open vs. laparoscopy-
assisted), and type of operation. The treatment failure rates were 3.1% in Group A
and 3.4% in Group B (absolute difference, -0.3%; 95% confidence interval [CI], 0.39
to 3.07, P=0.866), with SSI being the most common reason for failure in both groups
(2.7% in Group A and 3.0% in Group B [absolute difference, -0.3%; 95% CI, 0.37
to 3.37, P=0.846]). Cefotetan alone is as effective as triple antibiotics for prophy-
laxis in primary colorectal cancer patients undergoing elective surgery.
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and gentamicin (Gentamicin, Choongwae Pharma, Seoul,
Korea) (this protocol was used until July 2007). Group B=
cefotetan (Cefotetan, Kukje Pharm, Seongnam, Korea) alone
(this protocol was used from July 2007). 
Sodium phosphate (SP) was the most commonly used me-
chanical bowel preparation (MBP) regimen based on patient
tolerance. Polyethylene glycol (PEG) was used in patients >65
yr old or with comorbidity (including compromised renal
function or cardiovascular disease). MBP involved ingestion
of 2×45 mL SP or 4 L PEG two days before surgery. The
methods of patient preparation and antibiotic prophylaxis
are summarized in Table 1.
Demographic information including sex, age, body mass
index (BMI), medical history such as comorbidities (diabetes
mellitus, chronic obstructive pulmonary disease, and ischemic
heart disease including angina and myocardial infarction),
chemoradiation, oral steroid usage, and information on smok-
ing and alcohol ingestion immediately prior to surgery were
collected from all patients. Perioperative information regard-
ing diagnosis, surgical procedures, perioperative (within 2
weeks) transfusions, length of operation and pathology results
were also collected. 
Data on the following postoperative complications were
analyzed: surgery-related infections (i.e., surgical-site infec-
tions (SSI) occurring within the first 30 days after the proce-
dure), non-surgery related infection including pneumonia and
urinary tract infection, anastomotic leakage, and postopera-
tive ileus. SSI was defined according to a modification of the
Centers for Disease Control and Prevention (CDC) (11) and
included superficial incisional infection, infection of the deep
incision space and organ space infection. Superficial incision-
al infection was defined as that involving only skin and sub-
cutaneous tissue, and excluded stitch abscesses. Deep incisional
infection was defined as that involving deep soft tissues (e.g.,
fascia and muscle layers). Organ space infection was defined
as that involving any part of the anatomy that was opened or
manipulated during surgery (e.g., organs or spaces) other than
the incision and was diagnosed by abdominal computed tomog-
raphy (CT) scans. Anastomotic leakage was clinically defined
as symptoms and signs of peritonitis caused by anastomosis
leakage during the postoperative period. Physical examina-
tion (e.g., digital rectal examination), rigid sigmoidoscopy,
and/or abdominal CT scans were used to verify the leak.
Postoperative complications including SSI were evaluated
by at least two surgeons. Especially, SSI was classified accord-
ing to the agreement among the surgeons. 
Blood samples were obtained from peripheral veins before
surgery and on postoperative days 1 and 5. Laboratory param-
eters such as white blood cell (WBC) count, absolute neu-
trophil count (ANC), and C-reactive protein (CRP) levels
were analyzed to indicate inflammatory reactions. 
Treatment failure was defined as the presence of any post-
operative infection including SSI, anastomotic leakage and
pneumonia or urinary tract infection. 
Statistical analysis involved Pearson’s chi-square, Fisher’s
exact, or Student’s t tests, depending on the nature of the data.
A two-tailed P value <0.05 was considered to indicate a sig-
nificant difference.
Numbers in parentheses indicate the time of administration. 
*Antibiotics were administered per os; 
� Antibiotics were administered
intravenously within 60 min before skin incision; 
�
Antibiotics were admin-
istered intravenously at 8-hr intervals. 
Preop, preoperative day; POD, postoperative day; KM, kanamycin; MTZ,
metronidazole; EM, erythromycin; CZL, cefazolin; CTT, cefotetan; GM,
gentamicin. 
Preparations
Group A
January-June 2007
Group B
July-December 2007
Preop 2                       4 L polyethylene glycol (1,200 and 1,600) or
45 mL oral sodium phosphate (1,200 till 1,600)
Preop 1* KM 1 g  KM 1 g 
(1,200, 1,300, and 2,200) (1,200, 1,300, and 2,200)
MTZ 750 mg EM 1 g
(1,200 and 1,800) (1,200, 1,300, and 2,200)
Operation day
� CZL 2 g CTT 2 g
MTZ 500 mg
GM 80 mg
POD 1 to 3
� CZL 1 g CTT 1 g
GM 80 mg
MTZ 500 mg
POD 4 to 5
� CZL 1 g
GM 80 mg
Table 1. Methods of patient preparation and antibiotic prophy-
laxis
*Values are mean(s.d.) (range); 
� c2 test unless indicated otherwise; 
�
Stu-
dent’s t test. 
ASA, American Society of Anesthesiologists; COPD, chronic obstructive
pulmonary disease. Values in parentheses are percentages unless in-
dicated otherwise. 
Variables
Group A 
(n=225)
Group B
(n=236)
P value
�
Age (yr)* 59.6 (11.0)  60.5 (11.0)  0.384
�
(30-86) (16-81)
Male 142 (63.1) 156 (66.1) 0.502
Body mass index  23.7 (3.1) 23.5 (3.2) 0.574
�
(BMI) (kg/m
2)* (16.8-34.6) (15.2-34.0)
Obesity (BMI>30 kg/m
2) 5 (2.3) 5 (2.2) 0.944
Diabetes mellitus 34 (15.1) 39 (16.5) 0.678
COPD 2 (0.9) 7 (3.0) 0.177
Ischemic heart disease 4 (1.8) 5 (2.1) 1.000
Current smoker 43 (19.1) 45 (19.1) 0.991
ASA score (1:2:3:4) 104:115:6:0 81:142:12:1 0.056
Alcohol usage 113 (50.2) 138 (58.5) 0.075
Oral steroid use 1 (0.4) 2 (0.8) 1.000
Prior laparotomy 41 (18.2) 54 (22.9) 0.216
History of chemoradiation 49 (21.8) 59 (25.0) 0.414
Perioperative transfusion 23 (10.2) 35 (14.8) 0.136
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RESULTS
The demographic and clinical characteristics of patients are
shown in Table 2. The two groups showed no significant dif-
ferences in terms of age, sex, BMI, medical comorbidities,
past medical and social history. The two groups were also simi-
lar in terms of perioperative transfusions, location of prima-
ry tumors, surgery performed, surgery duration, and surgi-
cal pathology (Table 3). 
Postoperative outcomes are listed in Table 4. There were no
postoperative mortalities and anastomotic leakage. The over-
all morbidity rate was 5.4% (25/461), and the overall treat-
ment failure rate was 3.3% (15/461). The mean length of stay
and postoperative morbidity were similar for both groups.
The treatment failure rates were also similar, being 3.1% in
Group A and 3.4% in Group B (absolute difference, -0.3%;
95% confidence interval [CI], 0.39 to 3.07, P=0.866). The
overall SSI rate was 2.8% (13/461), and this was the most
common reason for treatment failure in both groups. The SSI
rates were similar for the two groups (2.7% in Group A and
3.0% in Group B [absolute difference, -0.3%; 95% CI, 0.37
to 3.37, P=0.846]). 
Nine (69%) of the 13 patients with SSI underwent conven-
tional open surgery, while the remaining four underwent lapa-
*Values are mean(s.d.) (range); 
� c2 test unless indicated otherwise; 
�
Stu-
dent’s t test. 
TPC, total proctocolectomy; Total, total colectomy; Subtotal, subtotal
colectomy. 
Variables
Group A 
(n=225)
Group B
(n=236)
P
value
�
Location of primary lesion 0.281
Rectum 93 (41.3) 123 (51.5)
Sigmoid colon 68 (30.2) 56 (23.7)
Descending colon 15 (6.7) 13 (5.5)
Transverse colon 13 (5.8) 10 (4.2)
Ascending colon 32 (14.2) 32 (13.6)
Synchronous multiple 4 (1.8) 2 (0.8)
Operations 0.258
Anterior resection 67 (29.8) 60 (25.4)
Low anterior resection 81 (36.0) 103 (43.6)
TPC/total/subtotal 7 (3.1) 2 (0.8)
Hartmann’s procedure 4 (1.8) 2 (0.8)
Abdominoperineal resection 10 (4.4) 16 (6.8)
Right hemicolectomy 42 (18.7) 38 (16.1)
Left hemicolectomy 13 (5.8) 15 (6.4)
Transverse colectomy 1 (0.4) 0 (0)
Surgical approach 0.064
Conventional open 42 (18.7) 61 (25.8)
Laparoscopy-assisted 183 (81.3) 1 75 (74.2)
Duration of operation (min)* 197 (78)  185 (63)  0.078
�
(55-462) (60-391)
Tumour stage 0.768
I 55 (24.4) 62 (26.3)
II 68 (30.2) 72 (30.5)
III 95 (42.2) 98 (41.5)
IV 7 (3.1) 4 (1.7)
Table 3. Diagnosis, type of surgery performed and pathology
findings
Fig. 1. Laboratory parameters.
*P<0.05.
Preop, preoperative; POD1, postoperative day 1; POD5, postoperative day 5. 
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Values in parentheses are percentages unless indicated otherwise.
*Values are mean(s.d.) (range); 
� c2 test unless indicated otherwise; 
�
Stu-
dent’s t test. 
Variables
Group A 
(n=225)
Group B
(n=236)
P
value
�
Length of stay (day)* 9.1 (4.3)  9.5 (4.3)  0.394
�
(5-43) (5-47)
Overall failure of prevention  7 (3.1) 8 (3.4) 0.866
Surgical site infection  6 (2.7) 7 (3.0) 0.846
Superficial incisional 3 5
Deep incisional 2 2
Organ-space 1 0
Anastomotic leakage 0 0
Pneumonia 0  (0) 1  (0.4)
Urinary tract infection 1 (0.4) 0 (0)
Postoperative ileus 6 (2.7) 4 (1.7) 0.536
Postoperative mortality  0 0
Table 4. Postoperative outcomes 
*
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roscopy-assisted surgery. The SSI rate after laparoscopy-assist-
ed surgery was 1.1% (4/358 patients), and this was lower than
after conventional open surgery (8.7%, 9/103) (P<0.05). 
Both groups were similar in terms of pre-operative WBC
count, ANC, and CRP levels (Fig. 1). Postoperatively, both
groups were similar to each other in terms of WBC count,
ANC, and CRP levels at postoperative 1 day, while WBC
count and ANC levels were lower in group B than group A
at postoperative day 5.
DISCUSSION
The second-generation cephalosporins have activity against
Gram-positive microbes and show improved toxicity against
Gram-negative bacteria, compared with that of first-genera-
tion cephalosporins. Among the second-generation antibi-
otics, cefotetan, a cephamycin, has excellent activity against
anaerobes (12) and is recommended for prophylaxis in colorec-
tal surgery patients (1). Cefoxitin, like cefotetan, is a cepha-
mycin, a second-generation cephalosporin with an antibac-
terial spectrum similar to that of cefotetan, and cefoxitin is
also recommended for colorectal surgery cases (1). However,
cefoxitin has a shorter half-life than cefotetan. A comparative
study showed that cefotetan levels remained higher than those
of cefoxitin after prolonged surgery (13). Many studies have
compared the prophylactic efficacy of cefotetan with that of
other antibiotics in elective colorectal surgery (5-10). A recent
study (10) showed that ertapenem, a long-acting carbapenem
antibiotic with wide coverage against Gram-positive, Gram-
negative, and anaerobic microbes, was more effective than
cefotetan in the prevention of SSI in patients undergoing elec-
tive colorectal surgery, but was more likely to increase the inci-
dence of C. difficile infection. Most studies have reported that
the efficacy of cefotetan is comparable to that of other antibac-
terials, both when cefotetan is compared to other antibiotic
combinations (5, 7, 8) and when cefotetan is compared to
multiple-dose regimens (6) of other antibacterial compounds.
It was thought that combination therapy offered both broad-
spectrum antibacterial activity and synergistic effects. How-
ever, a meta-analysis (14) found no difference between com-
bination therapy and monotherapy in terms of patient mor-
tality or the rate of resistance development. Furthermore, clin-
ical and bacteriological failures, as well as nephrotoxicity, were
more common in patients receiving combination treatments.
These findings encouraged us to change our routine antibi-
otic regimen and to conduct the present study. 
This work is a non-randomized comparative study exam-
ining the efficacy of cefotetan monotherapy, compared to con-
ventional triple antibiotic prophylaxis, in patients undergo-
ing elective colorectal cancer surgery. However, any bias result-
ing from non-randomization was minimized by prospective
collection of data from two groups of patients who had receiv-
ed different antibiotic regimens. The regimens were applied
during different periods, but for the same duration of 6 months,
before and after a change of antibiotic regimen. 
SSI is the most commonly encountered complication after
colorectal surgery. The reported rates of SSI following such
surgery range from 4.7% to 26.2% (6, 8-10, 15, 16). This
wide variation probably reflects between-study differences
in procedures (e.g., stoma-creating procedures, emergency
surgery, or multivisceral resection) and clinical settings, and
may also reflect differences in infection assessment periods.
Inflammatory bowel disease (IBD), diverticular disease,
stoma-creating procedures, multivisceral resection, and emer-
gency surgery can all increase the rate of postoperative infec-
tion. In a study of SSI that included all abdominal colorectal
operations (for IBD and diverticular disease) and emergency
surgery, Blummetti et al. (16) found an SSI rate of 24.5%.
Itani et al. (10) excluded patients who required emergency
surgery but included those with diverticulitis or IBD. These
authors found, in a modified intention-to-treat analysis, that
the SSI rate was 17.1% in an ertapenem group and 26.2%
in a cefotetan group. In a study of elective colorectal resection
patients that included IBD patients (19.9% of all patients)
and diverticular disease patients (9.7% of all patients), Smith
et al. (15) reported an incisional (superficial or deep) SSI rate
of 25.6%. Periti et al. (6) analyzed patients who underwent
elective colorectal surgery, including those with IBD or diver-
ticular disease, but excluding patients with severe IBD or
diverticular disease complicated by abscess or enterocutaneous
fistula. These authors reported SSI rates of 15.5% in cefoxitin-
treated patients and 10.1% in cefotetan-treated patients. 
The present study excluded patients undergoing emergency
surgery, surgery with palliative intent, surgery combined with
other organ resection, and local excision for homogenous inclu-
sions. We assessed infections that developed within 30 days
of surgery. A 30-day follow-up time is important to obtain
reliable data on the incidence of postoperative infections (17,
18). We found the SSI rate to be only 2.8% despite the rela-
tively long assessment period, a figure substantially lower
than reported in other studies. 
Several factors could account for the relatively low SSI rates
observed in the present study. The study excluded patients
undergoing ‘‘infection-prone’’ surgical procedures. In addi-
tion, there was a high proportion of laparoscopy-assisted oper-
ations (78.1%, 360/461 procedures). We found that laparo-
scopy-assisted surgery patients had lower SSI rates than con-
ventional open surgery patients (1.1% vs. 8.7%). This obser-
vation is consistent with the study by Braga et al. (19), who
reported that laparoscopic procedures were associated with
lower rates of postoperative infections, particularly wound
infections, than open procedures, in colorectal surgery cases.
This may be because of minimal wound contamination, short-
er incisions, and less manipulation of the intestine. The other
possible reason is that patients in the present study had a lower
average BMI than seen in Western patients. It has been report-
ed that SSI rates were greater in high-BMI than in low-BMIAntimicrobial Prophylaxis in Colorectal Cancer Surgery 433
patients (20), and that obesity was associated with SSI in pati-
ents undergoing colorectal surgery (10). The mean BMI of
our 461 patients was 23.6 kg/m2 (range, 15.2-34.6 kg/m2),
and 147 (31.9%) had a BMI ≥25 kg/m2. Only 10 patients
(2.2%) had a BMI ≥30 kg/m2. One study performed in the
United States (15) reported an incisional SSI rate of 25.6%
after elective colorectal resection, which was higher than pre-
dicted from the literature. The authors suggested that the
high figure may have reflected the large proportion of high
BMI patients (54% had BMI ≥25 kg/m2, and 23% had BMI
≥30 kg/m2). The proportion of overweight and obese patients
was thus higher in the cited study than in our present work. 
To our knowledge, no study has used laboratory data to
compare the efficacy of prophylactic antibiotics in colorectal
surgery cases. We analyzed WBC count, ANC, and CRP val-
ues. Under normal conditions neutrophils comprise about
60% of peripheral WBCs. An alteration in ANC can lead
to a change in the total WBC count. The peripheral WBC
count, including ANC, is a useful indicator of postoperative
infection, because of the important role of neutrophils in com-
bating such infection. Takahashi et al. (21) reported that an
increase in neutrophil count several days after surgery is one
of the most important signs of bacterial infection. CRP is an
important component of the acute-phase response and the
CRP response is very consistent (22). Postoperative CRP is
an indicator of the degree of trauma or the presence of infec-
tion. CRP concentrations rise in the immediate postoperative
period (4-12 hr) and reach maximal levels at 24-72 hr (23-
25). CRP is more sensitive in indicating postoperative infec-
tion than is the WBC count. A recent study (26) evaluating
the potential of CRP and WBC data to detect infectious com-
plications after rectal surgery showed that WBC counts did
not indicate unfavorable outcomes as early as CRP elevation.
In complicated cases, CRP elevation generally persisted after
postoperative day 2, whereas WBC counts were within nor-
mal ranges in the early postoperative period. We found that
our two groups were similar in terms of these laboratory para-
meters at postoperative day 1, but that both WBC counts and
ANCs were lower at postoperative day 5 in group B. How-
ever, these two parameters were within normal ranges in both
groups. In addition, CRP concentrations, which are more sen-
sitive to infection, decreased to near-normal levels at that time.
Overall, the effects of the two antibiotic regimens on the im-
mune response did not differ significantly. 
Considering the present finding that cefotetan alone is as
effective as triple antibiotics for prophylaxis in elective pri-
mary colorectal cancer surgery, we recommend the use of
cefotetan alone for such prophylaxis.
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